A cannabinoid system substance is a psychoactive compound that engages the endocannabinoid system — the endogenous signalling network built around the cannabinoid receptors CB1 and CB2, their lipid messengers, and the enzymes that synthesise and break them down.[1] Membership is defined functionally by activity at one or more components of this system, not by any single chemical scaffold.
The class spans three structurally distinct origins that converge on the same receptor system. Phytocannabinoids isolated from cannabis include THC, CBD, and side-chain homologues such as THCP, THCH, and THCB; the plant itself, cannabis, delivers them as a complex mixture. Synthetic cannabinoids — APICA, STS-135, THJ-018, THJ-2201 — are laboratory-designed agonists with no botanical relative.
Cannabinoids are used recreationally, medically (for chronic pain, chemotherapy-induced nausea, spasticity in multiple sclerosis, and certain seizure disorders), and traditionally in ritual and folk-medicine contexts. Across direct agonists the effect arc moves from relaxation, altered sensory perception, and appetite stimulation at lower exposures, through cognitive impairment and pronounced sedation at higher exposures, and — particularly with high-efficacy synthetic agonists — to acute psychiatric and cardiovascular crises.[2]
Pharmacology
The class converges on a single mechanistic endpoint — activation or modulation of the CB1 and CB2 receptors, both Gi/o-coupled GPCRs that suppress neurotransmitter release in the CNS and modulate cytokine signalling at the periphery.[1]
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| CB1 partial agonism | THC, cannabis | Activates CB1 to a submaximal ceiling, dampening glutamatergic and GABAergic release at CB1-enriched synapses[2] |
| CB1 full agonism | APICA, STS-135, THJ-018, THJ-2201, THCP | Drives CB1 to maximal activation without the partial-agonist ceiling, producing more intense and less predictable effects[3] |
| CB1 negative allosteric modulation | CBD | Binds an allosteric site on CB1 and reduces the efficacy of orthosteric agonists rather than activating the receptor directly[2] |
| Indirect endocannabinoid augmentation | CBD | Inhibits FAAH and raises anandamide tone, elevating endogenous cannabinoid signalling without occupying CB1 or CB2 directly[2] |
Within CB1 agonists, the pharmacologically critical distinction is full versus partial agonism. Partial agonists such as THC reach a submaximal activation ceiling even at receptor saturation, which limits the intensity of acute effects and helps preserve a margin between intoxication and severe toxicity.[2] Full agonists remove that ceiling and can drive cardiovascular, neurological, and psychiatric crises that partial agonists rarely produce.[3]
A second within-class axis is structural potency. The phytocannabinoid homologues differ from THC mainly in the length of their alkyl side chain, and longer chains extend deeper into the CB1 binding pocket, raising affinity and cannabimimetic potency.[4] The mechanistic endpoint is unchanged; the quantity needed to reach it shifts.
Substances
Prototypical members span the class's mechanistic range, from non-intoxicating allosteric modulators through partial agonists to high-efficacy synthetic full agonists:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| THC | Phytocannabinoid | Canonical reference compound; CB1 and CB2 partial agonist |
| Cannabis | Botanical mixture | Delivers THC together with many other cannabinoids and terpenes |
| CBD | Phytocannabinoid | Non-intoxicating; CB1 negative allosteric modulator with broad off-target activity |
| THCP | Phytocannabinoid homologue | Seven-carbon side chain confers markedly higher CB1 affinity than THC |
| THCH | Phytocannabinoid homologue | Six-carbon side chain variant of the THC scaffold |
| THCB | Phytocannabinoid homologue | Four-carbon side chain variant of the THC scaffold |
| Δ-10-THC | Phytocannabinoid isomer | Double-bond positional isomer of Δ-9-THC |
| Δ-11-THC | Phytocannabinoid isomer | Positional isomer related to the principal active metabolite of oral THC |
| APICA | Synthetic cannabinoid | Tetramethylcyclopropyl-indole CB1/CB2 full agonist |
| STS-135 | Synthetic cannabinoid | Fluoropentyl-indole CB1 full agonist |
| THJ-018 | Synthetic cannabinoid | Naphthoyl-indazole CB1 full agonist |
| THJ-2201 | Synthetic cannabinoid | Fluoropentyl naphthoyl-indazole CB1 full agonist |
These members share an end target — the cannabinoid receptors — but differ widely in intrinsic efficacy, binding affinity, and clinical risk profile, with synthetic full agonists carrying substantially greater acute toxicity than the phytocannabinoids.
Subjective Effects
Across the direct agonists the subjective trajectory tracks one axis: deepening CB1-mediated suppression of cortical and limbic neurotransmission as exposure rises.[5]
| Exposure | Characteristic effects |
|---|---|
| Low | Relaxation, mild euphoria, altered sensory perception, time dilation, appetite stimulation, mild analgesia |
| Moderate–high | Pronounced short-term memory impairment, reduced executive function, sedation, motor incoordination, tachycardia, anxiety in susceptible users |
| High | Perceptual distortion, dysphoria, acute panic, paranoia, transient psychotic symptoms, marked psychomotor impairment |
Because the same receptor mechanism drives both the sought and the unwanted effects, the margin between an enjoyable experience and an acutely distressing one narrows as exposure climbs. With high-efficacy full agonists the partial-agonist ceiling that softens the upper end of THC's profile is absent, and that margin narrows further.[3]
CBD does not follow this trajectory. As a negative allosteric modulator rather than an agonist, its profile is predominantly anxiolytic and lacks the euphoric-to-sedating arc of the direct agonists.
Safety
Risk profile
The defining acute danger of the class lies at its high-efficacy full-agonist end — the synthetic cannabinoids. Unlike phytocannabinoids, these compounds drive CB1 to maximal activation, and clinical surveillance has documented severe agitation, acute psychosis, seizures, tachyarrhythmias, myocardial infarction, acute kidney injury, and death following their use.[3][6]
The synthetic end of the class carries a further structural problem: the market cycles through many chemically distinct compounds whose human pharmacology is poorly characterised, products vary in potency between and within batches, and active metabolites can extend or alter the parent compound's profile.[7] Novel phytocannabinoid homologues such as THCP, THCH, and THCB share part of this uncertainty — their receptor pharmacology is partially documented, but controlled human dose-response data are sparse.
For phytocannabinoids and cannabis, the acute risk pattern is less severe but real. Acute anxiety and panic are the most common adverse events, particularly at high doses and in inexperienced users; transient cannabis-induced psychotic episodes are well documented, and pre-existing psychiatric vulnerability amplifies that risk.[8] Tachycardia is near-universal during acute intoxication and can precipitate ischaemic events in people with underlying cardiac disease. Psychomotor and attentional impairment sharply elevates accident risk during acute intoxication across the entire direct-agonist class.
Combination risks centre on additive sedation and cognitive impairment when cannabinoids are taken with alcohol, benzodiazepines, or opioids. Cannabinoids do not suppress brainstem respiration through the opioid mechanism, but their contribution to sedation, attentional fragmentation, and motor impairment compounds the risk profile of any depressant taken alongside them.
Tolerance & dependence
Repeated CB1 agonist exposure consistently produces tolerance, driven at the molecular level by receptor downregulation and desensitisation.[9] Cross-tolerance within the class is documented: tolerance built to one CB1 agonist transfers substantially to others, reflecting the shared receptor adaptation.[9]
Cannabinoid dependence is established and recognised diagnostically. Cannabis use disorder is a DSM-5 diagnosis characterised by compulsive use, failed cessation attempts, craving, tolerance, and withdrawal.[8] Psychological dependence — habitual use sustained by relief of dysphoria, anxiety, or sleep disturbance — is typically more prominent than physical dependence. Synthetic full agonists appear to drive dependence with greater speed and intensity, consistent with their higher receptor efficacy, though controlled longitudinal human data remain limited.
Cannabis withdrawal syndrome is a recognised clinical entity. Symptoms include irritability, anxiety, sleep disturbance with vivid dreams, decreased appetite, restlessness, depressed mood, and mild physical signs such as tremor, chills, and sweating; onset is typically within a day or two of cessation, intensity peaks over the first week, and symptoms resolve over the following weeks.[10] Unlike alcohol or benzodiazepine withdrawal, cannabinoid withdrawal is not life-threatening and does not carry a seizure risk.
Recovery
Cannabinoid dependence is treatable. CB1 receptor density recovers steadily during sustained abstinence, and withdrawal — while uncomfortable — runs a self-limiting course of weeks rather than months.[8] No medication has received regulatory approval specifically for cannabis use disorder, but psychosocial interventions, including cognitive-behavioural therapy and contingency management, have the strongest evidence base for supporting sustained abstinence. A clinician, addiction service, or withdrawal-management programme can help structure cessation, particularly for heavy long-term users or those with co-occurring psychiatric conditions.Recovery resources, crisis lines, and support pathways → View all
Sub-classes
Members
references
- [1] ^abLu, H.C. and Mackie, K. (2020) Review of the endocannabinoid system — Biological Psychiatry: Cognitive Neuroscience and Neuroimaging doi:10.1016/j.bpsc.2020.07.016
- [2]
- [3] ^abcdAlipour, A. and Patel, P.B. and Shabbir, Z. and Gabrielson, S. (2019) Review of the many faces of synthetic cannabinoid toxicities — Mental Health Clinician doi:10.9740/mhc.2019.03.093
- [4] ^Citti C, Linciano P, Russo F, Luongo L, Iannotta M, Maione S, Laganà A, Capriotti AL, Forni F, Vandelli MA, Gigli G, Cannazza G (2019) A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol — Scientific Reports doi:10.1038/s41598-019-56785-1
- [5]
- [6]